PR Newswire PHILADELPHIA, Nov. 15, 2024 PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of ...
PR Newswire BETHESDA, Md., Nov. 12, 2024 Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have ...
PR Newswire SHANGHAI, Nov. 11, 2024 – The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- Abbisko today announced ...
PR Newswire HOUSTON and SAN DIEGO, Nov. 11, 2024 TAC01-CLDN18.2 was well tolerated, with no dose-limiting toxicities and a favorable safety profile in the first two cohorts of the ongoing trial A pancreatic cancer patient treated with ...
PR Newswire SAN FRANCISCO, Nov. 11, 2024 SAN FRANCISCO, Nov. 11, 2024 /PRNewswire/ -- Optic, a digital biology company redefining drug discovery with AI, announced a collaboration with Vindur Tx, an early-stage oncology therapeutics venture. ...
PR Newswire ARCADIA, Calif., Nov. 11, 2024 ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ -- Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both ...
PR Newswire LOS ANGELES, Nov. 11, 2024 LOS ANGELES, Nov. 11, 2024 /PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted ...
PR Newswire CRANFORD, N.J., Nov. 11, 2024 Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% ...
PR Newswire SAN DIEGO, Nov. 11, 2024 Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors ...
PR Newswire TARRYTOWN, N.Y., Nov. 9, 2024 -ST101 Phase 2 data demonstrates activation of the tumor immune microenvironment in glioblastoma (GBM)- -ST316 Phase 1 data demonstrates antagonism of ß-catenin-driven immune exclusion- ...
Immunotherapy is a promising treatment that harnesses the immune system to combat cancer, but its effectiveness has been limited in treating gastrointestinal cancers. ...
Adding immunotherapy to neoadjuvant chemoradiation can improve survival and enable surgery in esophageal cancer, reveals research results published in a journal of the American Association for Cancer Research. Bottom Line In patients with unresectable, locally advanced esophageal cancer, the combination of radiation, chemotherapy, and immunotherapy increased the likelihood of tumors becoming surgically removable, leading to significantly better ...
A small clinical trial has shown encouraging outcomes for patients with triple-negative breast cancer who were treated with an experimental vaccine aimed at preventing tumor...
Cannabis consumption can wreak havoc on our cellular health, significantly increasing the risk of developing deadly cancerous tumors. In the study, published in the scientific journal Addiction Biology, cannabis is described as a ...
An investigational white button mushroom supplement shows promise in slowing and even preventing the spread of prostate cancer among men participating in a phase 2 clinical trial exploring food as medicine , suggests a new study led by a team ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers